BPC-157 Peptide: Research, Side Effects, Legality & Cost

BPC-157: the quick answer

What it is
BPC-157 is a synthetic peptide built from a 15-amino-acid sequence derived from a protein found in human gastric (stomach) juice. The name stands for Body Protection Compound-157.
Evidence level
Mostly animal and laboratory studies of tissue and gut repair. Robust human clinical trials are lacking.
Status
Not an approved medicine in the US or UK. In the US, HHS has said it does not intend to take enforcement action against state-licensed pharmacies that compound BPC-157 on its own, by subcutaneous or intramuscular injection, by mouth or on the skin, on a patient-specific prescription. This is interim enforcement discretion, not FDA approval.

This page is informational and does not diagnose, prescribe, or recommend therapies.

What is BPC-157?

BPC-157, sometimes called Body Protection Compound-157, is a synthetic peptide built from a 15-amino-acid sequence derived from a protein found in human gastric juice.

In laboratory and animal studies BPC-157 has been investigated for effects on blood-vessel formation, tendon and ligament cells and the gut lining, and researchers have explored signalling pathways linked to tissue repair. These findings come largely from preclinical models, and a described mechanism is not the same as a proven result in people.

Its US regulatory history is short and eventful. In 2023 the FDA restricted compounding of BPC-157 and a group of other peptides over safety concerns. It was removed from the FDA's restricted 503A compounding list in April 2026, the FDA's Pharmacy Compounding Advisory Committee voted in July 2026 to recommend it among six peptides, and on October 28, 2026 HHS announced the interim policy under which it may now be compounded on prescription.

On clinic directories BPC-157 appears in recovery, rehabilitation and gut-health contexts, often alongside TB-500, rather than as a mainstream prescription treatment.

What BPC-157 is used for

  • Recovery and rehabilitation clinics that discuss soft-tissue, tendon or ligament support, usually as one part of a wider plan.
  • Gut-health and functional-medicine settings, reflecting the peptide's origins in gastric research.
  • Performance and longevity providers who reference it alongside TB-500.
  • US compounding on prescription, by subcutaneous or intramuscular injection, by mouth or on the skin, within the interim HHS policy (see legal status below).

Legal status and the US policy's conditions

Claimed benefits vs what the evidence shows

The claims people most often search for about BPC-157, set against the research. The evidence level names the kind of study a claim rests on: cell (laboratory) studies, animal studies, human studies, or none. Educational only, not medical advice.

Overall: Preclinical only. Most research is animal and cell studies. Robust human clinical-trial evidence is lacking, so benefits in people should not be assumed. Human data: Insufficient. No large human trials establishing efficacy or long-term safety.

ClaimEvidence levelWhat the evidence shows
“Heals tendon and ligament injuries”AnimalAnimal studies suggest effects on tendon and soft-tissue repair, but robust human trials are lacking, so a proven injury-healing benefit in people should not be assumed.
“Repairs the gut and reverses IBD”AnimalAnimal models show gastrointestinal effects; human evidence for treating IBD or 'leaky gut' is not established.
“Speeds recovery when stacked with TB-500”NoneNo completed human trial has tested the combination, and a vial that blends the two has two active ingredients, which puts it outside the US policy.
“Free of side effects”Not establishedLong-term human safety has not been established in trials, and product quality varies widely across an unregulated supply chain.
“Pharma-grade and clinically proven”No approvalNo FDA-approved BPC-157 product exists and it has no MHRA marketing authorization; gray-market product is not independently verified for identity or purity.
“Used by elite athletes for faster recovery”Banned in sportBPC-157 falls under WADA's S0 (non-approved substances) category, so athletes face strict-liability anti-doping risk regardless of how it is marketed.

BPC-157 side effects and risks

What is known

BPC-157 has no established side-effect profile in people, because there are no large human trials. Its long-term safety in humans has not been established, and in 2023 the FDA restricted its compounding over safety concerns. The 2026 policy changed who may compound it, not the safety evidence.

What is not known

There is no established dosing and no long-term human data. What is said online about how it is tolerated does not come from large controlled studies, because none has been completed.

Product quality and gray-market vials

Outside the prescription route the supply chain is largely unregulated and product quality varies widely; gray-market product is not independently verified for identity or purity. A product compounded on prescription under the US policy has to meet its quality conditions; a 'research use only' vial meets none of them. The policy's conditions are under legal status.

Who should take particular care

  • Tested athletes. BPC-157 is prohibited at all times under WADA's S0 category, and strict liability applies.
  • Anyone offered a blend: BPC-157 with TB-500, or blends adding GHK-Cu or KPV, are outside the US policy.
  • Anyone buying 'research use only' or 'not for human consumption' vials, which the policy does not cover.

BPC-157 dosage: why this page gives no dose

There is no approved dose of BPC-157: no regulator has approved it, and no large human trial has established one. Under the US policy, a compounded BPC-157 product is made for one named patient on a prescription, so the amount, the route (subcutaneous or intramuscular injection, by mouth or on the skin) and the schedule are set by the prescriber.

BPC-157 amounts are usually quoted in micrograms, while vials are labeled in milligrams. Mixing the two up is a common arithmetic error, which is what the calculators below exist to prevent. They do not suggest an amount.

Peptide Clinic Finder does not give doses, and this page has no dosing chart. If you have been prescribed it, the amount, form and schedule are the prescriber's and the pharmacy's instructions, not a figure from a website.

  • BPC-157 dosage calculator: Turns a prescribed amount into concentration, volume and U-100 syringe units for a BPC-157 vial. Arithmetic only.
  • peptide calculator: The same arithmetic for any reconstituted vial, with a full reconstitution chart.

Questions to ask a prescriber or clinic about BPC-157

  • Why is BPC-157 being discussed for my goal specifically?
  • What evidence and safety limits should I understand first?
  • What monitoring or follow-up is built into the protocol?

What a credible provider tells you

  • A credible clinic should be upfront that BPC-157 is not a licensed medicine and that most evidence is preclinical, rather than implying proven results.
  • Expect a proper assessment of your history and goals, plus a clear explanation of sourcing, supervision, and follow-up before any protocol is discussed.
  • Be cautious if a provider cannot explain the regulatory status or treats BPC-157 as a routine, risk-free add-on.

Red flags

  • Guaranteed tissue-repair or injury-recovery claims.
  • No explanation of evidence quality, regulatory status, or sourcing.
  • No medical assessment before protocol discussion.

BPC-157 cost and US availability

Clinics usually bundle BPC-157 into a broader recovery, regenerative, or functional-medicine program rather than pricing it on its own, so the headline figure matters less than the clinician involvement, monitoring, and follow-up included. In the US, since the October 2026 HHS interim policy, some telehealth services price a compounded single-ingredient BPC-157 per month, if prescribed. Outside that route the supply chain is largely unregulated, so sourcing transparency matters as much as price. See the peptide therapy cost guide. For US readers, what the October 2026 HHS policy changed, what a prescription costs and how to tell it from a research-chemical seller are in our US guide to peptide prescriptions under the new compounding policy.

US telehealth prices for compounded BPC-157 are shown to US visitors. It is not a licensed medicine in the UK.

Frequently asked questions about BPC-157

What is BPC-157 used for?

BPC-157 is referenced mainly for recovery: tendon, ligament and other soft-tissue injuries, and gut health, often alongside TB-500. Those uses rest mostly on animal and laboratory studies; robust human clinical trials are lacking, so proven benefits in people should not be assumed.

Does BPC-157 work?

Most published research on BPC-157 comes from animal and laboratory studies looking at tissue and gut repair. High-quality human clinical trials are still lacking, so whether it works in people, and for what, is not established. Claims of proven benefits should be treated with caution.

Is BPC-157 safe?

That has not been established. There are no large human trials, so there is no established side-effect profile or long-term safety data, and product quality varies widely across an unregulated supply chain. In 2023 the FDA restricted its compounding over safety concerns. The 2026 policy changed who may compound it, not the safety evidence. Anyone considering it should do so only with a licensed clinician.

Is BPC-157 legal in the US?

Yes, within limits. Under an interim HHS policy announced on October 28, 2026 (published in the Federal Register on October 30), HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound BPC-157 acetate, as the only active ingredient, for an individual prescription, by subcutaneous or intramuscular injection, by mouth or on the skin, if the policy's conditions are met; an oral form needs documentation of adequate bioavailability. In practice a licensed US prescriber can order it for you from a state-licensed pharmacy, made from FDA-registered bulk ingredient. That is non-enforcement, not FDA approval, and HHS may revisit it. Blends such as BPC-157 with TB-500, 'research use only' products, supplements and 503B outsourcing facilities are outside it.

Is BPC-157 legal in the UK?

BPC-157 is not licensed as a medicine in the UK; no current UK marketing authorization was found in the MHRA Products register. It is not a controlled drug under the Misuse of Drugs Act.

Is BPC-157 FDA-approved in the US?

No. BPC-157 is not FDA-approved. It was removed from the FDA's restricted compounding list in April 2026, and under an interim HHS policy announced on October 28, 2026 (published in the Federal Register on October 30), HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound it, as the only active ingredient, for an individual prescription under set conditions. HHS says the policy does not grant FDA approval or establish safety and effectiveness, and that it may revisit it. BPC-157 remains an unapproved substance.

Why do some clinics offer BPC-157 if it isn't approved?

Some recovery, regenerative, and functional-medicine clinics reference BPC-157 within broader programs, operating in a regulatory gray area. Because of that, it is especially important to look for transparent clinician oversight, honest discussion of the evidence, and clear sourcing.

Is BPC-157 the same as TB-500?

No. BPC-157 is a 15-amino-acid sequence derived from a protein in gastric juice; TB-500 is based on a fragment of thymosin beta-4. Both rest mostly on animal research and are often discussed together in recovery contexts. Under the US policy each may be compounded only on its own (BPC-157 by subcutaneous or intramuscular injection, by mouth or on the skin; TB-500 by subcutaneous or intramuscular injection), so a blend of the two is outside it. In sport, TB-500 is prohibited at all times and BPC-157 falls under WADA's S0 category. See our BPC-157 vs TB-500 comparison.

Does Peptide Clinic Finder sell or recommend BPC-157?

No. Peptide Clinic Finder is an informational directory. We do not sell BPC-157, provide medical advice, or recommend its use — we help you compare how clinics position and supervise treatments so you can make an informed decision with a licensed clinician.

Related comparisons: BPC-157 vs TB-500, BPC-157 vs GHK-Cu, BPC-157 vs Ipamorelin.

Next step

Compare Providers and Next Steps

If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.

Related BPC-157 pages

Move from peptide research into clinic comparisons, guides, and matching.

Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.

Clinics offering BPC-157

The Catalyst Clinic

London, United Kingdom5.05.0 out of 5

Doctor-led peptide advisory consultations in central London. Every protocol is built around comprehensive bloodwork and personally led by Dr Ethan Hausman-Marquis, who reports a PhD from the Karolinska Institute, with compounds sourced from GMP-certified, EMA-regulated pharmacies.

  • Google 5.0 (48)
Doctor-led clinical governance
View Profile

The Forest Lounge Medical Center is a clinician-led peptide and longevity clinic in Lake Forest, Illinois. Care is delivered by licensed medical providers and covers peptide therapy, hormone optimization, metabolic health, recovery, performance and body composition, with plans based on individual goals, laboratory testing and ongoing monitoring.

  • Medical credentials
Physicians: Dr. Tarak Chokshi, MD and Dr. Richard Scuderi, MD, both listed in the federal NPI registry with Illinois medical license numbers on record.
View Profile

LiveNow Longevity

Las Vegas, NV, USA

LiveNow Longevity is a physician-led longevity and peptide clinic in Las Vegas — built on a simple promise: transparent medicine with no markup on your meds. Founded by board-certified neurologist Dr. Charles Kamen, MD, every patient starts with an $88 medical evaluation including baseline labs. From there, care can include peptide therapy, anti-aging treatments, GLP-1 weight loss (semaglutide and tirzepatide), NAD+ therapy, hormone optimization, and recovery support. In person in Las Vegas, or via telehealth across Nevada.

  • Doctor-led
Physician-led by Dr. Charles Kamen, MD
View Profile

Menon Health

London, United Kingdom

Menon Health is a Mayfair-based peptide therapy clinic founded by Dr Mukil Menon, a GMC-registered physician and one of the first doctors to prescribe medical peptide therapy in the UK. Before establishing Menon Health, Dr Menon served as UK medical director at Koniver Wellness, launching the clinic at Soho House London. He continues to practice within the NHS alongside his private consultations, ensuring his protocols stay grounded in current medical standards. The clinic offers doctor-led, prescription-based peptide therapy alongside regenerative cell complex treatments, bloods and diagnostics, and IV therapy. All formulations are sourced from GMP-certified, EMA-regulated pharmacies and dispensed as pre-filled pens, vials, or multi-peptide syringes — Menon Health's approach to combining multiple peptides in a single dose is designed to improve precision and patient adherence. Based at 64 North Row in Mayfair, London, Menon Health serves patients across the UK, Europe, Canada, and the United States, with consultations available in person or remotely.

  • Google 3.7 (3)
GMC-registered physicians

Peptide therapy from £450

View Profile

Explore clinics by city

What to do next

Move from treatment research into provider comparison by choosing the next step that fits your buying journey. Some users want to compare programs first, while others want a faster route into matched options or local clinic discovery.

Next step

Explore suitable clinics

Move from peptide research into real provider comparison by checking city pages, cost context, and related treatment comparisons. Clinics vary more by oversight and program structure than by peptide name alone.

Map preview
Mapbox map preview

For clinics

Are you a clinic?

Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.